SIGA TECHNOLOGIES INC

Form 4/A

October 22, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

OMB APPROVAL

burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

[SIGA]

(Middle)

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * MJALLI ADNAN M M

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol SIGA TECHNOLOGIES INC

(Check all applicable)

(Last) (First)

3. Date of Earliest Transaction

_X__ Director Officer (give title

X__ 10% Owner Other (specify

C/O TRANSTECH PHARMA. INC., 4170 MENDENHALL OAKS

(Street)

PARKWAY, SUITE 110

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year) 10/02/2009

(Month/Day/Year)

09/30/2009

X Form filed by One Reporting Person Form filed by More than One Reporting

4,317,618

I

6. Individual or Joint/Group Filing(Check

Person

HIGH POINT, NC 27265

\$0.0001 per 09/30/2009

Stock

(City)	(State)	(Zip) Table	e I - Non-D	erivative Secu	rities Acquired,	Disposed of, or	Beneficially (Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities And Disposed of (Instr. 3, 4 and Amount	<i>'</i>	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value	00/20/2000		V	1 045 206	\$	4 217 610	T	by TransTech

1,845,396 A

Pharma, share Inc. (2) ("Common Stock") F Common 09/30/2009 444,666 \$ 7.8 3,872,952 Ι D by

X

TransTech Pharma,

Edgar Filing: SIGA TECHNOLOGIES INC - Form 4/A

Common Stock Stoc

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour Numbe Shares
Warrant (right to buy)	\$ 1.8784	09/30/2009		X		1,845,396	01/08/2004	01/08/2011	Common Stock	1,845

Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting of the France France	Director	10% Owner	Officer	Other		
MJALLI ADNAN M M						
C/O TRANSTECH PHARMA, INC.	v	\mathbf{v}				
4170 MENDENHALL OAKS PARKWAY, SUITE 110	X	X				
HIGH POINT, NC 27265						

Signatures

Adnan M. M.
Mjalli

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Reporting Owners 2

Edgar Filing: SIGA TECHNOLOGIES INC - Form 4/A

On September 30, 2009, TransTech Pharma, Inc. sold 3,851,969 shares of Common Stock in a privately negotiated transaction to STH Partners, L.P.

The shares of Common Stock and the warrants were beneficially owned by TransTech Pharma, Inc. The reporting person is the

(2) President, Chief Executive Officer and a director of TransTech Pharma, Inc. The reporting person disclaims beneficial ownership of the securities beneficially owned by TransTech Pharma, Inc. except to the extent of his pecuniary interest therein.

Remarks:

This amendment is filed to restate the original Form 4. The number of shares shown in this restated Form 4 reflects an anti-di Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.